MeSH D017497 - hidradenitis suppurativa
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Biocon | Adalimumab | Hulio | 2020-07-06 | |||
| Sandoz | Adalimumab | Halimatoz | 2018-07-26 | |||
| Adalimumab | Hefiya | 2018-07-26 | ||||
| Adalimumab | Hyrimoz | 2018-10-30 | ||||
| Boehringer Ingelheim | Adalimumab | Cyltezo | 2017-08-25 | |||
| AbbVie | Adalimumab | Humira | 2002-12-31 | $13,133 M | Q2/23-Q1/24 | |
| Pfizer | Adalimumab | Abrilada | 2019-11-15 | |||
| Adalimumab | Amsparity | 2020-02-13 | ||||
| Abbott Biotherapeutics | Adalimumab | Trudexa | 2003-09-01 | |||
| Celltrion | Adalimumab | Yuflyma | 2023-05-23 | |||
| Fresenius Kabi | Adalimumab | Idacio | 2022-12-13 | |||
| Adalimumab | Kromeya | 2019-04-02 | ||||
| Amgen | Adalimumab | Amgevita | 2017-03-21 | |||
| Adalimumab | Amjevita | 2016-09-23 | ||||
| Adalimumab | Solymbic | 2017-03-22 | ||||
| Stada Arzneimittel | Adalimumab | Hukyndra | 2021-11-15 | |||
| Adalimumab | Libmyris | 2021-11-12 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
50%5/10
Phase 2
7%2/29
Phase 3
50%3/6
Approved: 2Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use